Supply Chain Intelligence

Dianthus Therapeutics, Inc. Supply Chain

DNTH supply chain intelligence for Dianthus Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

DNTH ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

8Suppliers
6Customers
3Debt Items
20Related Chains

Dianthus Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
LGND Ligand Pharmaceuticals Incorporated 72% tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
LGND Ligand Pharmaceuticals Incorporated 72% Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activ…
LGNZZ LGNZZ 72% Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing acti…
LGNZZ LGNZZ 72% tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNTH graph: . Commercial Should any of our pr…
SNYNF Sanofi 72% . Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal inf…
ZBIO Zenas BioPharma, Inc. 72% Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: . Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to c…
ZBIO Zenas BioPharma, Inc. 72% . Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal inf…

Dianthus Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
TENACIA TENACIA 92% Pursuant to the Tenacia Option, if Tenacia exercises the option and pays the Company the option exercise fee related to the second antibody sequence, the Company will grant Tenacia an exclusive licen…
ZENAS ZENAS 90% The Company assessed the Zenas Agreements in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606), and concluded that it represented a contract with a customer and was within the …
LGND Ligand Pharmaceuticals Incorporated 72% tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
LGND Ligand Pharmaceuticals Incorporated 72% Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activ…
LGNZZ LGNZZ 72% tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
LGNZZ LGNZZ 72% Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing A…

Dianthus Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
DNTH-DEBT-9107 Xbrl Convertible 90% xbrl convertible detail from xbrl 2023-12-31.
DNTH-DEBT-9106 Warrants outstanding: 0.001 90% xbrl warrant detail from xbrl 2025-12-31.
DNTH-DEBT Debt stack $1.4M 90% Market cache reports total debt of $1.4M.

Dianthus Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
DNTH-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 243 tracked holders.

Dianthus Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CLYM Climb Bio, Inc. 100.00 2
LGNZZ LIGAND PHARMACEUTICALS INC 100.00 1 ['customer', 'supplier']
AZN AstraZeneca PLC 100.00 2
LGND Ligand Pharmaceuticals Incorporated 100.00 1 ['customer', 'supplier']
BHC Bausch Health Companies Inc. 100.00 2
BMY Bristol-Myers Squibb Company 100.00 2
BMYMP Bristol-Myers Squibb Co 100.00 2
TKPHF Takeda Pharmaceutical Company Limited 100.00 2
NUVB Nuvation Bio Inc. 100.00 2
SNYNF Sanofi 100.00 2 ['supplier']
LLY Eli Lilly and Company 100.00 2
VRDN Viridian Therapeutics, Inc. 100.00 2
XNCR Xencor, Inc. 100.00 2
ZENAS ZENAS 60.75 1 ['receiving']
LONA LeonaBio, Inc. 50.00 2
OABIW OmniAb, Inc. 50.00 2
SGMO Sangamo Therapeutics, Inc. 50.00 2
ELUT Elutia Inc. 50.00 2
PLX Protalix BioTherapeutics, Inc. 50.00 2
PVLA Palvella Therapeutics, Inc. 50.00 2
View DNTH supply chain intel →

Explore the full interactive supply chain map for Dianthus Therapeutics, Inc..

Open DNTH supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map